All the news articles and press releases in one place.

Date / Time Source Company Sector Market Cap Announcement
22Dec17 21:42 GNW Novartis AG Health 208,186m Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22Dec17 06:15 GNW Novartis AG Health 208,186m Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
15Dec17 06:00 GNW Novartis AG Health 208,186m Novartis announces Oncology head to retire
15Dec17 06:00 GNW Novartis AG Health 208,186m Novartis announces Oncology head to retire
11Dec17 15:50 GNW Novartis AG Health 208,186m Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
10Dec17 15:38 GNW Novartis AG Health 208,186m Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
08Dec17 06:15 GNW Novartis AG Health 208,186m Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07Dec17 06:00 GNW Novartis AG Health 208,186m Novartis tender offer for Advanced Accelerator Applications commences
06Dec17 18:15 GNW Novartis AG Health 208,186m Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
30Nov17 06:15 GNW Novartis AG Health 208,186m Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
29Nov17 22:00 GNW Novartis AG Health 208,186m Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
27Nov17 06:15 GNW Novartis AG Health 208,186m Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
20Nov17 06:15 GNW Novartis AG Health 208,186m Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
15Nov17 14:00 GNW Novartis AG Health 208,186m Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
14Nov17 06:15 GNW Novartis AG Health 208,186m Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
14Nov17 06:10 GNW Novartis AG Health 208,186m New data reinforces clinical basis for switching to Sandoz biosimilar medicines
13Nov17 17:00 GNW Novartis AG Health 208,186m Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 17:00 GNW Novartis AG Health 208,186m Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 06:00 GNW Novartis AG Health 208,186m Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 06:00 GNW Novartis AG Health 208,186m Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 02:51 GNW Novartis AG Health 208,186m Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
12Nov17 18:30 GNW Novartis AG Health 208,186m New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
11Nov17 13:00 GNW Novartis AG Health 208,186m Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
10Nov17 22:51 GNW Novartis AG Health 208,186m Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
08Nov17 06:15 GNW Novartis AG Health 208,186m Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
07Nov17 06:15 GNW Novartis AG Health 208,186m Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
06Nov17 06:15 GNW Novartis AG Health 208,186m Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
06Nov17 06:10 GNW Novartis AG Health 208,186m Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
02Nov17 20:30 GNW Novartis AG Health 208,186m Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
01Nov17 13:05 GNW Novartis AG Health 208,186m Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
31Oct17 06:15 GNW Novartis AG Health 208,186m Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
30Oct17 06:15 GNW Novartis AG Health 208,186m Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30Oct17 06:00 GNW Novartis AG Health 208,186m Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30Oct17 06:00 GNW Novartis AG Health 208,186m Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
28Oct17 07:55 GNW Novartis AG Health 208,186m Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
27Oct17 06:15 GNW Novartis AG Health 208,186m Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25Oct17 16:30 GNW Novartis AG Health 208,186m Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
24Oct17 06:00 GNW Novartis AG Health 208,186m Novartis delivered growth on top and bottom line in all divisions in Q3
24Oct17 06:00 GNW Novartis AG Health 208,186m Novartis delivered growth on top and bottom line in all divisions in Q3
23Oct17 06:15 GNW Novartis AG Health 208,186m Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
18Oct17 06:15 GNW Novartis AG Health 208,186m Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
06Oct17 06:15 GNW Novartis AG Health 208,186m Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL
02Oct17 06:15 GNW Novartis AG Health 208,186m Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
28Sep17 06:15 GNW Novartis AG Health 208,186m Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
22Sep17 06:15 GNW Novartis AG Health 208,186m Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
20Sep17 06:15 GNW Novartis AG Health 208,186m Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
16Sep17 15:00 GNW Novartis AG Health 208,186m Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
14Sep17 06:15 GNW Novartis AG Health 208,186m Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
13Sep17 06:15 GNW Novartis AG Health 208,186m Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
12Sep17 06:15 GNW Novartis AG Health 208,186m Sandoz proposed biosimilar rituximab accepted for review by the FDA
10Sep17 23:05 GNW Novartis AG Health 208,186m Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
09Sep17 10:00 GNW Novartis AG Health 208,186m Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
07Sep17 21:30 GNW Novartis AG Health 208,186m Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
05Sep17 06:15 GNW Novartis AG Health 208,186m Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
04Sep17 06:00 GNW Novartis AG Health 208,186m Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
04Sep17 06:00 GNW Novartis AG Health 208,186m Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
30Aug17 16:04 GNW Novartis AG Health 208,186m Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30Aug17 16:04 GNW Novartis AG Health 208,186m Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
28Aug17 08:00 GNW Novartis AG Health 208,186m Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
28Aug17 08:00 GNW Novartis AG Health 208,186m Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
27Aug17 10:00 GNW Novartis AG Health 208,186m Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
27Aug17 10:00 GNW Novartis AG Health 208,186m Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
24Aug17 06:15 GNW Novartis AG Health 208,186m Novartis appoints Bertrand Bodson as Chief Digital Officer
24Aug17 06:10 GNW Novartis AG Health 208,186m Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
21Aug17 06:15 GNW Novartis AG Health 208,186m Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
25Jul17 06:15 GNW Novartis AG Health 208,186m Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
21Jul17 12:20 GNW Novartis AG Health 208,186m Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
18Jul17 06:00 GNW Novartis AG Health 208,186m Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18Jul17 06:00 GNW Novartis AG Health 208,186m Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
14Jul17 18:22 GNW Novartis AG Health 208,186m Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
12Jul17 22:24 GNW Novartis AG Health 208,186m Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
12Jul17 22:20 GNW Novartis AG Health 208,186m Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
06Jul17 07:52 GNW Novartis AG Health 208,186m Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
29Jun17 06:15 GNW Novartis AG Health 208,186m Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
23Jun17 17:00 GNW Novartis AG Health 208,186m NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
23Jun17 09:40 GNW Novartis AG Health 208,186m Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23Jun17 07:40 GNW Novartis AG Health 208,186m Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23Jun17 07:35 GNW Novartis AG Health 208,186m Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
22Jun17 22:42 GNW Novartis AG Health 208,186m Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22Jun17 06:15 GNW Novartis AG Health 208,186m Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
22Jun17 06:15 GNW Novartis AG Health 208,186m Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
21Jun17 06:15 GNW Novartis AG Health 208,186m Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
20Jun17 06:15 GNW Novartis AG Health 208,186m Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:15 GNW Novartis AG Health 208,186m Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:10 GNW Novartis AG Health 208,186m Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
19Jun17 06:15 GNW Novartis AG Health 208,186m Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
17Jun17 06:15 GNW Novartis AG Health 208,186m Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
15Jun17 19:00 GNW Novartis AG Health 208,186m FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
15Jun17 06:15 GNW Novartis AG Health 208,186m Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
08Jun17 21:30 GNW Novartis AG Health 208,186m Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
07Jun17 16:30 GNW Novartis AG Health 208,186m Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
06Jun17 06:15 GNW Novartis AG Health 208,186m Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
05Jun17 21:05 GNW Novartis AG Health 208,186m Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05Jun17 12:15 GNW Novartis AG Health 208,186m Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
04Jun17 14:00 GNW Novartis AG Health 208,186m Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
02Jun17 06:15 GNW Novartis AG Health 208,186m Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
31May17 06:10 GNW Novartis AG Health 208,186m Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
31May17 06:00 GNW Novartis AG Health 208,186m At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
31May17 06:00 GNW Novartis AG Health 208,186m At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
30May17 22:00 GNW Novartis AG Health 208,186m Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Date / Time Source Company % Chg
22Dec17 21:42 GNW Novartis AG 0.70%
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22Dec17 06:15 GNW Novartis AG 0.70%
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
15Dec17 06:00 GNW Novartis AG 0.70%
Novartis announces Oncology head to retire
15Dec17 06:00 GNW Novartis AG 0.70%
Novartis announces Oncology head to retire
11Dec17 15:50 GNW Novartis AG 0.70%
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
10Dec17 15:38 GNW Novartis AG 0.70%
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
08Dec17 06:15 GNW Novartis AG 0.70%
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07Dec17 06:00 GNW Novartis AG 0.70%
Novartis tender offer for Advanced Accelerator Applications commences
06Dec17 18:15 GNW Novartis AG 0.70%
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
30Nov17 06:15 GNW Novartis AG 0.70%
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
29Nov17 22:00 GNW Novartis AG 0.70%
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
27Nov17 06:15 GNW Novartis AG 0.70%
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
20Nov17 06:15 GNW Novartis AG 0.70%
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
15Nov17 14:00 GNW Novartis AG 0.70%
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
14Nov17 06:15 GNW Novartis AG 0.70%
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
14Nov17 06:10 GNW Novartis AG 0.70%
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
13Nov17 17:00 GNW Novartis AG 0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 17:00 GNW Novartis AG 0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 06:00 GNW Novartis AG 0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 06:00 GNW Novartis AG 0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 02:51 GNW Novartis AG 0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
12Nov17 18:30 GNW Novartis AG 0.70%
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
11Nov17 13:00 GNW Novartis AG 0.70%
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
10Nov17 22:51 GNW Novartis AG 0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
08Nov17 06:15 GNW Novartis AG 0.70%
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
07Nov17 06:15 GNW Novartis AG 0.70%
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
06Nov17 06:15 GNW Novartis AG 0.70%
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
06Nov17 06:10 GNW Novartis AG 0.70%
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
02Nov17 20:30 GNW Novartis AG 0.70%
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
01Nov17 13:05 GNW Novartis AG 0.70%
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
31Oct17 06:15 GNW Novartis AG 0.70%
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
30Oct17 06:15 GNW Novartis AG 0.70%
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30Oct17 06:00 GNW Novartis AG 0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30Oct17 06:00 GNW Novartis AG 0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
28Oct17 07:55 GNW Novartis AG 0.70%
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
27Oct17 06:15 GNW Novartis AG 0.70%
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25Oct17 16:30 GNW Novartis AG 0.70%
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
24Oct17 06:00 GNW Novartis AG 0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
24Oct17 06:00 GNW Novartis AG 0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
23Oct17 06:15 GNW Novartis AG 0.70%
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
18Oct17 06:15 GNW Novartis AG 0.70%
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
06Oct17 06:15 GNW Novartis AG 0.70%
Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL
02Oct17 06:15 GNW Novartis AG 0.70%
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
28Sep17 06:15 GNW Novartis AG 0.70%
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
22Sep17 06:15 GNW Novartis AG 0.70%
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
20Sep17 06:15 GNW Novartis AG 0.70%
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
16Sep17 15:00 GNW Novartis AG 0.70%
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
14Sep17 06:15 GNW Novartis AG 0.70%
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
13Sep17 06:15 GNW Novartis AG 0.70%
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
12Sep17 06:15 GNW Novartis AG 0.70%
Sandoz proposed biosimilar rituximab accepted for review by the FDA
10Sep17 23:05 GNW Novartis AG 0.70%
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
09Sep17 10:00 GNW Novartis AG 0.70%
Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
07Sep17 21:30 GNW Novartis AG 0.70%
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
05Sep17 06:15 GNW Novartis AG 0.70%
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
04Sep17 06:00 GNW Novartis AG 0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
04Sep17 06:00 GNW Novartis AG 0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
30Aug17 16:04 GNW Novartis AG 0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30Aug17 16:04 GNW Novartis AG 0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
28Aug17 08:00 GNW Novartis AG 0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
28Aug17 08:00 GNW Novartis AG 0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
27Aug17 10:00 GNW Novartis AG 0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
27Aug17 10:00 GNW Novartis AG 0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
24Aug17 06:15 GNW Novartis AG 0.70%
Novartis appoints Bertrand Bodson as Chief Digital Officer
24Aug17 06:10 GNW Novartis AG 0.70%
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
21Aug17 06:15 GNW Novartis AG 0.70%
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
25Jul17 06:15 GNW Novartis AG 0.70%
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
21Jul17 12:20 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
18Jul17 06:00 GNW Novartis AG 0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18Jul17 06:00 GNW Novartis AG 0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
14Jul17 18:22 GNW Novartis AG 0.70%
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
12Jul17 22:24 GNW Novartis AG 0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
12Jul17 22:20 GNW Novartis AG 0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
06Jul17 07:52 GNW Novartis AG 0.70%
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
29Jun17 06:15 GNW Novartis AG 0.70%
Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
23Jun17 17:00 GNW Novartis AG 0.70%
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
23Jun17 09:40 GNW Novartis AG 0.70%
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23Jun17 07:40 GNW Novartis AG 0.70%
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23Jun17 07:35 GNW Novartis AG 0.70%
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
22Jun17 22:42 GNW Novartis AG 0.70%
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22Jun17 06:15 GNW Novartis AG 0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
22Jun17 06:15 GNW Novartis AG 0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
21Jun17 06:15 GNW Novartis AG 0.70%
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
20Jun17 06:15 GNW Novartis AG 0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:15 GNW Novartis AG 0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:10 GNW Novartis AG 0.70%
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
19Jun17 06:15 GNW Novartis AG 0.70%
Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
17Jun17 06:15 GNW Novartis AG 0.70%
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
15Jun17 19:00 GNW Novartis AG 0.70%
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
15Jun17 06:15 GNW Novartis AG 0.70%
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
08Jun17 21:30 GNW Novartis AG 0.70%
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
07Jun17 16:30 GNW Novartis AG 0.70%
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
06Jun17 06:15 GNW Novartis AG 0.70%
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
05Jun17 21:05 GNW Novartis AG 0.70%
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05Jun17 12:15 GNW Novartis AG 0.70%
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
04Jun17 14:00 GNW Novartis AG 0.70%
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
02Jun17 06:15 GNW Novartis AG 0.70%
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
31May17 06:10 GNW Novartis AG 0.70%
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
31May17 06:00 GNW Novartis AG 0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
31May17 06:00 GNW Novartis AG 0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
30May17 22:00 GNW Novartis AG 0.70%
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Date / Time Company % Chg
22Dec17 21:42 Novartis AG 0.70%
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22Dec17 06:15 Novartis AG 0.70%
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
15Dec17 06:00 Novartis AG 0.70%
Novartis announces Oncology head to retire
15Dec17 06:00 Novartis AG 0.70%
Novartis announces Oncology head to retire
11Dec17 15:50 Novartis AG 0.70%
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
10Dec17 15:38 Novartis AG 0.70%
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
08Dec17 06:15 Novartis AG 0.70%
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07Dec17 06:00 Novartis AG 0.70%
Novartis tender offer for Advanced Accelerator Applications commences
06Dec17 18:15 Novartis AG 0.70%
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
30Nov17 06:15 Novartis AG 0.70%
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
29Nov17 22:00 Novartis AG 0.70%
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
27Nov17 06:15 Novartis AG 0.70%
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
20Nov17 06:15 Novartis AG 0.70%
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
15Nov17 14:00 Novartis AG 0.70%
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
14Nov17 06:15 Novartis AG 0.70%
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
14Nov17 06:10 Novartis AG 0.70%
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
13Nov17 17:00 Novartis AG 0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 17:00 Novartis AG 0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 06:00 Novartis AG 0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 06:00 Novartis AG 0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 02:51 Novartis AG 0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
12Nov17 18:30 Novartis AG 0.70%
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
11Nov17 13:00 Novartis AG 0.70%
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
10Nov17 22:51 Novartis AG 0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
08Nov17 06:15 Novartis AG 0.70%
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
07Nov17 06:15 Novartis AG 0.70%
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
06Nov17 06:15 Novartis AG 0.70%
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
06Nov17 06:10 Novartis AG 0.70%
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
02Nov17 20:30 Novartis AG 0.70%
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
01Nov17 13:05 Novartis AG 0.70%
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
31Oct17 06:15 Novartis AG 0.70%
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
30Oct17 06:15 Novartis AG 0.70%
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30Oct17 06:00 Novartis AG 0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30Oct17 06:00 Novartis AG 0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
28Oct17 07:55 Novartis AG 0.70%
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
27Oct17 06:15 Novartis AG 0.70%
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25Oct17 16:30 Novartis AG 0.70%
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
24Oct17 06:00 Novartis AG 0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
24Oct17 06:00 Novartis AG 0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
23Oct17 06:15 Novartis AG 0.70%
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
18Oct17 06:15 Novartis AG 0.70%
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
06Oct17 06:15 Novartis AG 0.70%
Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL
02Oct17 06:15 Novartis AG 0.70%
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
28Sep17 06:15 Novartis AG 0.70%
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
22Sep17 06:15 Novartis AG 0.70%
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
20Sep17 06:15 Novartis AG 0.70%
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
16Sep17 15:00 Novartis AG 0.70%
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
14Sep17 06:15 Novartis AG 0.70%
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
13Sep17 06:15 Novartis AG 0.70%
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
12Sep17 06:15 Novartis AG 0.70%
Sandoz proposed biosimilar rituximab accepted for review by the FDA
10Sep17 23:05 Novartis AG 0.70%
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
09Sep17 10:00 Novartis AG 0.70%
Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
07Sep17 21:30 Novartis AG 0.70%
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
05Sep17 06:15 Novartis AG 0.70%
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
04Sep17 06:00 Novartis AG 0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
04Sep17 06:00 Novartis AG 0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
30Aug17 16:04 Novartis AG 0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30Aug17 16:04 Novartis AG 0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
28Aug17 08:00 Novartis AG 0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
28Aug17 08:00 Novartis AG 0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
27Aug17 10:00 Novartis AG 0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
27Aug17 10:00 Novartis AG 0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
24Aug17 06:15 Novartis AG 0.70%
Novartis appoints Bertrand Bodson as Chief Digital Officer
24Aug17 06:10 Novartis AG 0.70%
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
21Aug17 06:15 Novartis AG 0.70%
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
25Jul17 06:15 Novartis AG 0.70%
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
21Jul17 12:20 Novartis AG 0.70%
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
18Jul17 06:00 Novartis AG 0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18Jul17 06:00 Novartis AG 0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
14Jul17 18:22 Novartis AG 0.70%
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
12Jul17 22:24 Novartis AG 0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
12Jul17 22:20 Novartis AG 0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
06Jul17 07:52 Novartis AG 0.70%
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
29Jun17 06:15 Novartis AG 0.70%
Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
23Jun17 17:00 Novartis AG 0.70%
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
23Jun17 09:40 Novartis AG 0.70%
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23Jun17 07:40 Novartis AG 0.70%
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23Jun17 07:35 Novartis AG 0.70%
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
22Jun17 22:42 Novartis AG 0.70%
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22Jun17 06:15 Novartis AG 0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
22Jun17 06:15 Novartis AG 0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
21Jun17 06:15 Novartis AG 0.70%
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
20Jun17 06:15 Novartis AG 0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:15 Novartis AG 0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:10 Novartis AG 0.70%
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
19Jun17 06:15 Novartis AG 0.70%
Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
17Jun17 06:15 Novartis AG 0.70%
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
15Jun17 19:00 Novartis AG 0.70%
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
15Jun17 06:15 Novartis AG 0.70%
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
08Jun17 21:30 Novartis AG 0.70%
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
07Jun17 16:30 Novartis AG 0.70%
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
06Jun17 06:15 Novartis AG 0.70%
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
05Jun17 21:05 Novartis AG 0.70%
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05Jun17 12:15 Novartis AG 0.70%
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
04Jun17 14:00 Novartis AG 0.70%
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
02Jun17 06:15 Novartis AG 0.70%
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
31May17 06:10 Novartis AG 0.70%
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
31May17 06:00 Novartis AG 0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
31May17 06:00 Novartis AG 0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
30May17 22:00 Novartis AG 0.70%
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients